Related Experiment Videos
[Personal experience with replacement therapy with intravenous gamma globulin]
J Litzman1, J Lokaj, D Stikarovská
1Ustav klinické imunologie LF Masarykovy univerzity, FN u sv. Anny, Brno.
Vnitrni Lekarstvi
|November 1, 1995
Summary
Intravenous immunoglobulin (IVIG) therapy significantly improved health and reduced infections in patients with antibody deficiency. Monitoring serum IgG levels is crucial for effective treatment.
Area of Science:
- Immunology
- Internal Medicine
- Pharmacology
Context:
- Antibody deficiency disorders, such as common variable immunodeficiency (CVID) and x-linked agammaglobulinemia (XLA), necessitate immunoglobulin replacement therapy.
- Intravenous immunoglobulin (IVIG) is the preferred treatment, but patient experiences and optimal monitoring require further elucidation.
Purpose:
- To present a 30-month experience with IVIG replacement therapy in patients with CVID and XLA.
- To evaluate the efficacy, safety, and laboratory monitoring parameters of long-term IVIG treatment.
Summary:
- This study details IVIG treatment in 12 patients (8 CVID, 4 XLA) over 30 months, using a dosage of 400 mg/kg every 3-4 weeks.
- Ten patients reported improved health, particularly reduced chronic bronchitis symptoms. No pneumonia cases occurred during IVIG treatment, compared to two cases prior.
- An infusion rate of 4 mg/kg/min was well-tolerated by most patients, highlighting serum trough IgG levels as a key monitoring parameter.
Impact:
- IVIG therapy demonstrates significant clinical benefits for patients with antibody deficiency, including improved respiratory health and reduced infection rates.
- The findings support the established efficacy of IVIG and provide practical insights into safe administration and essential laboratory monitoring for long-term patient management.